• Giulia Scioscia, Cosimo Carlo De Pace, Giulio Giganti, Pasquale Tondo, Foschino BarbaroMaria PiaMPDepartment of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.Respiratory Medicine Unit, "Policlinico Foggia" University Hospital, Foggia, Italy., and Donato Lacedonia.
• Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy.
• Ir J Med Sci. 2023 Oct 1; 192 (5): 230123032301-2303.

BackgroundThe SARS-CoV-2 pandemic has prompted clinicians to develop an early and effective treatment of viral infections. To date, vaccines, monoclonal antibodies, and antivirals are the cornerstone of therapy for SARS-CoV-2. AIFA approved the prescription of molnupiravir on 30/12/2021. Molnupiravir is a prodrug that causes the accumulation of errors in the viral genome.MethodsWe prescribed molnupiravir to a total of 74 patients in a range between 26 and 96 years old and followed-up them for 30 days. 10 patients affected by idiopathic pulmonary fibrosis (IPF) were treated.ResultsThe follow-up showed that all of the treated patients presented a regression of symptoms. No patients were hospitalized and/or showed sequelae after the infection by SARS-CoV-2, even though the examined population was older and with more co-morbidities than other patients treated with different antivirals.ConclusionMolnupiravir is safe and well-tolerated by patients with high-risk of progression to severe COVID. No patients were hospitalized or showed sequelae, including all patients affected by IPF.© 2022. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland.

14 keywords...

hide…